Tags

Type your tag names separated by a space and hit enter

Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
Arterioscler Thromb Vasc Biol. 2009 Mar; 29(3):416-23.AT

Abstract

BACKGROUND

Rimonabant, the first selective cannabinoid type 1 (CB1) receptor antagonist, improves cardiometabolic risk factors in overweight/obese patients. ADAGIO-Lipids assessed the effect of rimonabant on cardiometabolic risk factors and intraabdominal and liver fat.

METHODS AND RESULTS

803 abdominally obese patients with atherogenic dyslipidemia (increased triglycerides [TG] or reduced high-density lipoprotein-cholesterol [HDL-C]) were randomized to placebo or rimonabant 20 mg/d for 1 year. HDL-C and TG were coprimary end points. Intraabdominal (visceral) and liver fat were measured by computed tomography in a subgroup of 231 patients. In total, 73% of rimonabant- and 70% of placebo-treated patients completed the study treatment. Rimonabant 20 mg produced significantly greater changes from baseline versus placebo in HDL-C (+7.4%) and TG levels (-18%; P<0.0001), as well as low-density lipoprotein (LDL) and HDL particle sizes, apolipoprotein A1 and B, HDL2, HDL3, C-reactive protein, and adiponectin levels (all P<0.05). Rimonabant decreased abdominal subcutaneous adipose tissue (AT) cross-sectional area by 5.1% compared to placebo (P<0.005), with a greater reduction in visceral AT (-10.1% compared to placebo; P<0.0005), thereby reducing the ratio of visceral/subcutaneous AT (P<0.05). Rimonabant significantly reduced liver fat content (liver/spleen attenuation ratio; P<0.005). Systolic (-3.3 mm Hg) and diastolic (-2.4 mm Hg) blood pressure were significantly reduced with rimonabant versus placebo (P<0.0001). The safety profile of rimonabant was consistent with previous studies; gastrointestinal, nervous system, psychiatric, and general adverse events were more common with rimonabant 20 mg.

CONCLUSIONS

In abdominally obese patients with atherogenic dyslipidemia, rimonabant 20 mg significantly improved multiple cardiometabolic risk markers and induced significant reductions in both intraabdominal and liver fat.

Authors+Show Affiliations

Québec Heart Institute, Hôpital Laval Research Centre, Université Laval, Québec, Canada. jean-pierre.despres@crhl.ulaval.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19112166

Citation

Després, Jean-Pierre, et al. "Effect of Rimonabant On the High-triglyceride/ low-HDL-cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat: the ADAGIO-Lipids Trial." Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 3, 2009, pp. 416-23.
Després JP, Ross R, Boka G, et al. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol. 2009;29(3):416-23.
Després, J. P., Ross, R., Boka, G., Alméras, N., & Lemieux, I. (2009). Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arteriosclerosis, Thrombosis, and Vascular Biology, 29(3), 416-23. https://doi.org/10.1161/ATVBAHA.108.176362
Després JP, et al. Effect of Rimonabant On the High-triglyceride/ low-HDL-cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat: the ADAGIO-Lipids Trial. Arterioscler Thromb Vasc Biol. 2009;29(3):416-23. PubMed PMID: 19112166.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. AU - Després,Jean-Pierre, AU - Ross,Robert, AU - Boka,Gabor, AU - Alméras,Natalie, AU - Lemieux,Isabelle, AU - ,, Y1 - 2008/12/26/ PY - 2008/12/30/entrez PY - 2008/12/30/pubmed PY - 2009/3/6/medline SP - 416 EP - 23 JF - Arteriosclerosis, thrombosis, and vascular biology JO - Arterioscler. Thromb. Vasc. Biol. VL - 29 IS - 3 N2 - BACKGROUND: Rimonabant, the first selective cannabinoid type 1 (CB1) receptor antagonist, improves cardiometabolic risk factors in overweight/obese patients. ADAGIO-Lipids assessed the effect of rimonabant on cardiometabolic risk factors and intraabdominal and liver fat. METHODS AND RESULTS: 803 abdominally obese patients with atherogenic dyslipidemia (increased triglycerides [TG] or reduced high-density lipoprotein-cholesterol [HDL-C]) were randomized to placebo or rimonabant 20 mg/d for 1 year. HDL-C and TG were coprimary end points. Intraabdominal (visceral) and liver fat were measured by computed tomography in a subgroup of 231 patients. In total, 73% of rimonabant- and 70% of placebo-treated patients completed the study treatment. Rimonabant 20 mg produced significantly greater changes from baseline versus placebo in HDL-C (+7.4%) and TG levels (-18%; P<0.0001), as well as low-density lipoprotein (LDL) and HDL particle sizes, apolipoprotein A1 and B, HDL2, HDL3, C-reactive protein, and adiponectin levels (all P<0.05). Rimonabant decreased abdominal subcutaneous adipose tissue (AT) cross-sectional area by 5.1% compared to placebo (P<0.005), with a greater reduction in visceral AT (-10.1% compared to placebo; P<0.0005), thereby reducing the ratio of visceral/subcutaneous AT (P<0.05). Rimonabant significantly reduced liver fat content (liver/spleen attenuation ratio; P<0.005). Systolic (-3.3 mm Hg) and diastolic (-2.4 mm Hg) blood pressure were significantly reduced with rimonabant versus placebo (P<0.0001). The safety profile of rimonabant was consistent with previous studies; gastrointestinal, nervous system, psychiatric, and general adverse events were more common with rimonabant 20 mg. CONCLUSIONS: In abdominally obese patients with atherogenic dyslipidemia, rimonabant 20 mg significantly improved multiple cardiometabolic risk markers and induced significant reductions in both intraabdominal and liver fat. SN - 1524-4636 UR - https://www.unboundmedicine.com/medline/citation/19112166/Effect_of_rimonabant_on_the_high_triglyceride/_low_HDL_cholesterol_dyslipidemia_intraabdominal_adiposity_and_liver_fat:_the_ADAGIO_Lipids_trial_ L2 - http://www.ahajournals.org/doi/full/10.1161/ATVBAHA.108.176362?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -